Summary: In 1222 patients with type 2 diabetes recently hospitalised for worsening heart failure, sotagliflozin started before or shortly after discharge reduced the total of cardiovascular deaths and heart failure hospitalisations and urgent visits compared with placebo (51.0 vs 76.3 events per 100 patient-years; hazard ratio 0.67; 95% CI 0.52 to 0.85) over a median of 9.0 months. The trial ended early after loss of funding.
PICO Summary
| Element | Detail |
|---|---|
| Population | 1222 patients with type 2 diabetes recently hospitalised for worsening heart failure; multicentre, double-blind, randomised, placebo-controlled trial; median follow-up 9.0 months. |
| Intervention | Sotagliflozin (n=608); first dose given before discharge in 48.8% and a median of 2 days after discharge in 51.2%. |
| Comparison | Placebo (n=614). |
| Outcome | Total cardiovascular deaths and hospitalisations and urgent visits for heart failure: 245 vs 355 events; 51.0 vs 76.3 per 100 patient-years; HR 0.67 (95% CI 0.52 to 0.85); p<0.001. Cardiovascular death: 10.6 vs 12.5 per 100 patient-years; HR 0.84 (95% CI 0.58 to 1.22). Death from any cause: 13.5 vs 16.3 per 100 patient-years; HR 0.82 (95% CI 0.59 to 1.14). Diarrhoea 6.1% vs 3.4%; severe hypoglycaemia 1.5% vs 0.3%; hypotension 6.0% vs 4.6%; acute kidney injury 4.1% vs 4.4%. |
Expert Commentary
My verdict is positive, with a caveat about precision. The question here was one of timing: is it safe and useful to start this class around discharge after an admission for decompensated heart failure? In 1222 patients with type 2 diabetes, sotagliflozin started before discharge or a median of 2 days after it lowered the total of cardiovascular deaths and heart failure hospitalisations and urgent visits (51.0 against 76.3 events per 100 patient-years; hazard ratio 0.67; 95% CI 0.52 to 0.85). Hypotension (6.0% against 4.6%) and acute kidney injury (4.1% against 4.4%) were similar, which answers the usual worry about early initiation. The limitation is that the trial ended early because the sponsor withdrew funding, so it is small, with a median follow-up of 9.0 months, and it cannot tell us about mortality (cardiovascular death hazard ratio 0.84; 95% CI 0.58 to 1.22). Diarrhoea (6.1% against 3.4%) and severe hypoglycaemia (1.5% against 0.3%) were more common with the drug. Can I use this with my patients? Yes, as support for not waiting. In a patient with type 2 diabetes admitted with worsening heart failure, I would start treatment before or soon after discharge, once the patient is stable. A larger trial that also enrols patients without diabetes would be welcome.
References
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183. PMID: 33200892.

